



Dedicated To Life

February 9, 2024

BSE Limited

Listing Department
P J Towers, Dalal Street,
Fort, Mumbai-400 001
Scrip Code: 532321

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, 5th floor, Plot No. – C/1, G
Block, Bandra-Kurla Complex, Bandra (E)
Mumbai – 400 051
NSE Symbol: ZYDUSLIFE

Dear Sir / Madam,

Sub: Intimation regarding promoters' intention to participate in the Buyback.

This in in continuation of our letter dated February 9, 2024 with regard to the approval granted by the Board of Directors of the Company to undertake buyback of not exceeding 59,70,149 (Fifty Nine Lakh Seventy Thousand One Hundred Forty Nine) fully paid-up equity shares of the Company, each having a face value of INR 1/- (“**Equity Shares**”), representing up to 0.59% of the total number of equity shares in the paid-up equity share capital of the Company, at a price of INR 1,005/- (Indian Rupees One Thousand Five only) per Equity Share payable in cash for an aggregate amount not exceeding INR 600,00,00,000/- (Indian Rupees Six Hundred Crores only) (“**Buyback**”), on a proportionate basis through the “tender offer” route, in accordance with the provisions the under the Companies Act, 2013, and rules made thereunder and the SEBI Buy-Back of Securities) Regulations, 2018, as amended (“**Buyback Regulations**”), and other applicable law.

In terms of the Buyback Regulations, under the tender offer route, the members of the promoter and promoter group of the Company (“**Promoter Group**”) and persons in control of the Company have the option to participate in the Buyback. We would like to inform that members of the Promoter Group and persons in control of the Company, *vide* their letters dated February 9, 2024, have communicated their intention to participate in the Buyback and tender Equity Shares based on their entitlement and to offer such number of additional Equity Shares, if so required, to ensure that post the Buyback the Company continues to be in compliance with the minimum public shareholding norms as prescribed under applicable laws.

We request you to kindly take the above on record.

Thanking you,
Yours sincerely,

For, **Zydus Lifesciences Limited**

Dhaval Soni
Company Secretary & Compliance Officer

